|By PR Newswire||
|January 28, 2014 10:51 PM EST||
NEW YORK, Jan. 28, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Thoratec Corporation ("Thoratec" or the "Company") (NASDAQ: THOR), concerning whether the board has breached its fiduciary duties to shareholders.
One of the Company's products, the HeartMate II Left Ventricular Assist Device was recalled by U.S. regulators on April 4, 2012 amid concern for a potentially life threatening defect. Then, on November 27, 2013, the New England Journal of Medicine released a study stating that the use of the HeartMate II was related to increased rates of "pump thrombosis" and was associated with "substantial morbidity and mortality."
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Thoratec shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP